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Amyloid-beta related angiitis (ABRA) of the central nervous system (CNS) is a rare disorder
with overlapping features of primary angiitis of the CNS and cerebral amyloid angiopathy.
We evaluated a 74-year-old man with intermittent left sided weakness and MRI findings
of leptomeningeal enhancement, vasogenic edema, and subcortical white matter disease
proven to have ABRA. We discuss clinicopathological features and review the topic of
ABRA.
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CASE REPORT
A 74-year-old man with a past medical history of chronic lym-
phocytic leukemia (CLL) stage 0 (not receiving treatment), renal
cell carcinoma (clear cell type, nuclear grade II-untreated), hyper-
tension, and hyperlipidemia awoke one morning with numbness
of the thumb and first two fingers of the left hand “marching” up
to the left arm over the course of few seconds. This was immedi-
ately followed by drooling from the left corner of his mouth. The
entire episode lasted <15 s and was followed by complete resolu-
tion. The following day, he had an episode of slurred speech and
left facial weakness, which prompted evaluation at a local hospital
where his symptoms again completely resolved. He was admitted
for further investigation. Contrast-enhanced brain MRI showed
leptomeningeal enhancement and increased signal intensity on
T2 fluid attenuated inversion recovery (FLAIR) sequences on the
right temporal lobe, as well as moderate subcortical and periven-
tricular T2 signal abnormalities suggestive of white matter disease
(Figures 1A–D). He was diagnosed as possibly having “herpes
encephalitis” and intravenous Acyclovir was administered. Cere-
brospinal fluid (CSF) analysis showed a white blood cell (WBC)
count of 2 cells/µL, red blood cell count of 83 cells/µL, glucose
of 61 mg/dL, and protein content of 282 mg/dL (normal range
15–45 mg/dL). Herpes simplex virus PCR was negative, and thus,
Acyclovir was discontinued. Other laboratory analyses included an
erythrocyte sedimentation rate (ESR) of 40 mm/h, a positive anti-
nuclear antibody (titer unavailable), and negative anti-neutrophil
cytoplasmic antibodies (ANCAs). During that hospital stay, he
had several similar episodes of marching numbness involving his
left hand and facial asymmetry without loss of consciousness or
adventitious limb movements. Electroencephalogram (EEG) was
normal. He received Levetiracetam 500 mg twice daily that was
subsequently increased to 750 mg twice daily. He was discharged
home without a definite diagnosis. However, the next day, he
developed severe pain over the right temple and presented to
another institution where a second MRI showed similar findings,
and a right temporal leptomeningeal biopsy showed intramural
as well as perivascular inflammatory infiltrates with granuloma-
tous features in the leptomeninges and penetrating blood vessels
associated with vasculopathic changes, as well as positive label-
ing for beta-amyloid on immunohistochemical studies consistent
with amyloid-beta related angiitis (ABRA). He was then referred
to our Medical Center for follow-up and management. Upon
initial evaluation by us, neurologic examination was normal. How-
ever, 2 days later, he had mild right lower extremity weakness and
slurred speech prompting hospital admission to our institution.
A third brain MRI showed a new left frontal leptomeningeal area
of enhancement and scattered FLAIR abnormalities on the left
temporal lobe without evidence of acute infarction. MRI of the
cervical spine showed no intrinsic cord changes (Figures 2A–D).
EEG showed diffuse slow wave abnormalities. He received a 5-day
course of 1000 mg intravenous methylprednisolone followed by
a daily maintenance dose of 60 mg prednisone. Mycophenolate
mofetil was chosen for immunosuppression in lieu of cyclophos-
phamide, given his CLL. The patient has remained neurologically
stable since hospital discharge.
DISCUSSION
Amyloid-beta related angiitis is a predominantly granuloma-
tous angio-destructive inflammatory mediated disease affecting
leptomeningeal and cortical vessels characterized by meningeal
lymphocytosis and abundant amyloid-beta deposition within the
vessel walls (1, 2). Although sharing characteristics of both PACNS
and cerebral amyloid angiopathy (CAA), ABRA has some differ-
entiating clinical and pathological features. PACNS has an annual
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FIGURE 1 | (A,B) T1 contrast-enhanced axial MRI shows evidence of right
temporal leptomeningeal enhancement. (C) T2 FLAIR shows right temporal
lobe vasogenic edema. (D) Scattered subcortical white matter disease.
incidence of 2.4:1,000,000 and is diagnosed by the presence of
acquired neurologic or psychiatric deficits and classic angiographic
or histologic findings of CNS angiitis, unaccounted for by other
systemic causes or disease mimics (3). CAA, characterized by beta-
amyloid deposition (primarily the more soluble form of Aβ 1–40)
within leptomeningeal and cortical vessels is found in 30–50%
of asymptomatic elderly subjects and in approximately 80% of
patients with Alzheimer’s disease. Moreover, CAA accounts for
one third of all lobar hemorrhages in elderly subjects (4). A neu-
ropathological variant of ABRA characterized by non-destructive
perivascular inflammatory infiltration and amyloid deposition is
known as CAA-related inflammation (CAA-RI) (5, 6). Patients
with CAA-RI share most of the clinical features of ABRA, and
most often present with seizures, and/or cognitive decline (5, 6).
Both entities share similar clinical features that respond similarly
to treatment (2).
The pathophysiology of ABRA is not fully understood. Whether
amyloid-beta deposits initiate a vasculitic response or rather
angiopathic-mediated inflammation leads to beta-amyloid depo-
sition remains debatable. One theory suggests an immunologic
response toward amyloid-beta, resulting in leptomeningeal and
parenchymal inflammation with increased amyloid-beta depo-
sition and clearance of amyloid-beta in the parenchyma (1).
Decreasing levels of Aβ 1–40 and Aβ 1–42 CSF autoantibodies
in two patients (one CAA-RI one ABRA) after steroid therapy
further suggest an autoimmune response (2). The presence of par-
tially activated CD4+ T-cells in the CSF (7), vasculitic changes in
response to vascular amyloid in transgenic mice that develop CAA
(8), and favorable response to steroids and immunosuppressive
therapy supports an immune-mediated pathogenesis.
FIGURE 2 | (A,B) T1 contrast-enhanced axial MRI shows new left frontal
leptomeningeal enhancement. (C) T2 FLAIR shows new left temporal lobe
changes. (D) T2 sagittal view of the cervical spine showed no evidence of
intrinsic cord abnormalities.
Amyloid-beta related angiitis usually presents in the seventh
decade of life (mean age of 67 years) – without gender predilec-
tion (1). The main clinical features of ABRA, in order of fre-
quency, include mental status and cognitive changes followed by
headaches, seizures, and focal neurologic deficits (1, 2, 9, 10). In
addition, patients may rarely present with uveomeningitis (11),
posterior reversible encephalopathy-like manifestations, (10) or
progression to coma (12).
An abnormal ESR has been reported in 12–38% of patients
with ABRA (1, 2). In the series by Scolding et al., none of the
21 patients tested had positive ANCAs. In contrast, CSF abnor-
malities are extremely common and present in 85% of patients.
Protein content elevation has been found in 60–90% of patients,
with a median level of 100 mg/dL. Primarily, lymphocytic pleocy-
tosis with a WBC count>5 cells has been observed in 50% of cases
(1, 2). CSF oligoclonal bands have been absent in all patients tested
by Scolding et al. (1). In one report, CSF tau and Aβ 42 were found
to be normal in one patient with positive oligoclonal bands (13).
CSF flow cytometric analyses have shown predominantly CD4+
T-cells (7). The most common APOE genotype found when com-
pared to non-inflammatory CAA patients was APOE4, present in
71–76% of tested patients (5, 6).
The most common neuroimaging findings of ABRA are
gadolinium-enhancing leptomeninges (2). Other findings include
non-specific white matter changes, vasogenic edema, mass lesions,
infarctions, and/or intracerebral hemorrhages (1, 2, 9, 10). Lep-
tomeningeal or cortical hemosiderin deposits are observed in some
cases (5, 7, 14) but unlike CAA, cerebral hemorrhages are less
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frequent (1, 2). Angiographic abnormalities are also infrequent
(2, 5). Most common EEG abnormalities are diffuse slow wave
changes (1).
Treatment of ABRA and CAA-RI include corticosteroids and
immunosuppression, primarily with cyclophosphamide (1, 2, 5,
6). In one series, 5/6 patients with CAA-RI clinically improved
with treatment, returning to their premorbid status. Four out of
these five patients demonstrated MRI improvement, and only two
deaths were reported between 2 and 3 years from initial presenta-
tion (5). In another series of 12 patients with CAA-RI, 7 improved
within 1–2 weeks of treatment, 3 patients had relapses while not
receiving treatment, and 2 patients showed no clinical response
(6). In the series by Salvari et al., 10/28 patients with ABRA were
treated with steroids alone, and 13/28 patients were treated with a
combination of steroids and immunosuppression for 5–8 months
(nine cyclophosphamide, four other agents). Those treated with
steroids+ immunosuppression fared better than patients with
CAA but not differently than patients with PACNS. In the series by
Scolding et al., approximately one in four patients required a sur-
gical intervention such as CSF diversion, mass lesion resection, or
craniotomy. Mortality in ABRA has been reported to be between
7 and 44% (1, 2).
Amyloid-beta related angiitis and CAA-RI are unusual neu-
ropathological diagnoses. Mental status or cognitive changes,
gadolinium-enhancing meninges, and elevated CSF protein con-
tent are frequent findings. In contrast to PACNS, patients with
ABRA have better response to immunosuppressive therapy. Dif-
ferentiating prognostic and management features between ABRA
and CAA-RI require further refinement.
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APPENDIX
PATHOLOGY
Brain biopsy showed cortical and subcortical white matter with perivascular chronic intramural inflammatory infiltrates with fibrinoid
deposition along with granulomatous features involving meningeal and superficial penetrating arteries. In many instances, the inflam-
matory changes were associated with deposition of amorphous eosinophilic material in the vessel walls consistent with amyloid. Congo
red and β-amyloid immunohistochemical stain were positive.
FIGURE A1 | (A,B) Leptomeningeal and cortical blood vessels with
granulomatous inflammation and surrounding hemorrhage, 40× and 100×.
(C) Cortical vessel with inflammation and fibrinoid necrosis, 200×. (D) Vessel
with granulomatous inflammation and amyloid deposition, 400×. (E) Congo
red stain positive for amyloid, 400×. (F) Congo stain showing characteristic
apple-green birefringence under polarized light, 400×.
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